Where Will Hershey Stock Be In 1 Year?
Chocolate stocks used to be the epitome of sleepy stability,…
Sell
40
COR Quote, Financials, Valuation and Earnings
Last price:
$295.76
Seasonality move
:
3.54%
Day range:
$289.03 - $297.63
52-week range:
$218.65 - $309.35
Dividend yield:
0.74%
P/E ratio:
33.78x
P/S ratio:
0.19x
P/B ratio:
55.72x
Volume:
1.2M
Avg. volume:
1.4M
1-year change:
30.86%
Market cap:
$56.4B
Revenue:
$294B
EPS (TTM):
$8.62
Analysts' Opinion
-
Consensus RatingCencora has received a consensus rating of Buy. The company's average rating is a Buy based on 10 Buy ratings, 5 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $323.16, Cencora has an estimated upside of 10.99% from its current price of $291.17.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $257.45 representing 11.58% downside risk from its current price of $291.17.
Fair Value
-
According to the consensus of 15 analysts, Cencora has 10.99% upside to fair value with a price target of $323.16 per share.
COR vs. S&P 500
-
Over the past 5 trading days, Cencora has underperformed the S&P 500 by -1.26% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Cencora does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Cencora has grown year-over-year revenues for 51 quarters straight. In the most recent quarter Cencora reported revenues of $75.5B.
Earnings Growth
-
Cencora has grown year-over-year earnings for 1 quarter straight. In the most recent quarter Cencora reported earnings per share of $3.68.
Enterprise value:
62.5B
EV / Invested capital:
--
Price / LTM sales:
0.19x
EV / EBIT:
23.94x
EV / Revenue:
0.20x
PEG ratio (5yr expected):
2.14x
EV / Free cash flow:
17.48x
Price / Operating cash flow:
16.05x
Enterprise value / EBITDA:
16.82x
Gross Profit (TTM):
$10.5B
Return On Assets:
2.51%
Net Income Margin (TTM):
0.55%
Return On Equity:
183.42%
Return On Invested Capital:
24.2%
Operating Margin:
1.59%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | $247.5B | $276.5B | $310.2B | $68.4B | $75.5B | |
| Gross Profit | $8.4B | $9.5B | $10.5B | $2.5B | $3.1B | |
| Operating Income | $2.6B | $2.9B | $3.5B | $877.5M | $1.2B | |
| EBITDA | $3B | $3.7B | $3.7B | $823.6M | $1.3B | |
| Diluted EPS | $7.78 | $9.14 | $8.62 | $2.09 | $3.68 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $35.5B | $39.4B | $40B | $44.2B | $46.5B | |
| Total Assets | $47B | $57.3B | $58.8B | $63.9B | $71.2B | |
| Current Liabilities | $33B | $42.8B | $45.1B | $49.8B | $53.3B | |
| Total Liabilities | $47.1B | $56.4B | $58.3B | $62.6B | $70B | |
| Total Equity | -$102.8M | $906.1M | $511.1M | $1.2B | $1.2B | |
| Total Debt | $6.2B | $6.5B | $4.9B | $5.2B | $7.9B | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $2.9B | $2.6B | $4.1B | -$878.4M | $3.4B | |
| Cash From Investing | -$1.6B | -$1.2B | -$4.8B | -$166.5M | -$4.1B | |
| Cash From Financing | -$3.1B | -$717.4M | $614.9M | $323.2M | -$491.7M | |
| Free Cash Flow | $2.4B | $2.1B | $3.6B | -$991.2M | $3.2B | |
COR
Sector
Market Cap
$56.4B
$33.7M
Price % of 52-Week High
94.12%
47.76%
Dividend Yield
0.74%
0%
Shareholder Yield
2.39%
-0.82%
1-Year Price Total Return
30.86%
-34.27%
Beta (5-Year)
0.571
0.625
Dividend yield:
0.74%
Annualized payout:
$2.04
Payout ratio:
25.13%
Growth streak:
19 years
Technicals
8-day SMA
Sell
Level
$295.24
200-day SMA
Buy
Level
$256.61
Bollinger Bands (100)
Buy
Level
259.06 - 294.14
Chaikin Money Flow
Buy
Level
398.1M
20-day SMA
Sell
Level
$292.49
Relative Strength Index (RSI14)
Sell
Level
48.18
ADX Line
Sell
Level
13.8
Williams %R
Neutral
Level
-75.0826
50-day SMA
Buy
Level
$290.33
MACD (12, 26)
Buy
Level
1.89
25-day Aroon Oscillator
Buy
Level
56
On Balance Volume
Neutral
Level
365.9M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (4.8843)
Sell
CA Score
(Annual)
Level (-0.7789)
Buy
Beneish M-Score
(Annual)
Level (-2.5284)
Buy
Momentum Score
Level (8)
Sell
Ohlson Score
Level (2.064)
Buy
Piotroski F Score
(Annual)
Level (7)
Sell
Quality Ratio Score
Level (3)
Buy
Fundamental Score
Level (6)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Cencora is one of three domestic leading pharmaceutical wholesalers. It sources and distributes branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospital networks, and healthcare providers. It and McKesson and Cardinal Health constitute over 90% of the US pharmaceutical wholesale industry. Cencora also provides commercialization services for manufacturers of pharmaceuticals and medical devices, global specialty drug logistics (World Courier), and animal health product distribution (MWI Animal Health). Cencora expanded its international presence in 2021 by purchasing Alliance Healthcare, one of the leading drug wholesalers in Europe.
Stock Forecast FAQ
In the current month, COR has received 10 Buy ratings 5 Hold ratings, and 0 Sell ratings. The COR average analyst price target in the past 3 months is $323.16.
-
Where Will Cencora Stock Be In 1 Year?
According to analysts, the consensus estimate is that Cencora share price will rise to $323.16 per share over the next 12 months.
-
What Do Analysts Say About Cencora?
Analysts are divided on their view about Cencora share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Cencora is a Sell and believe this share price will drop from its current level to $257.45.
-
What Is Cencora's Price Target?
The price target for Cencora over the next 1-year time period is forecast to be $323.16 according to 15 Wall Street analysts, 10 of them rate the stock a Buy, 0 rate the stock a Sell, and 5 analysts rate the stock a Hold.
-
Is COR A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Cencora is a Buy. 10 of 15 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of COR?
You can purchase shares of Cencora via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Cencora shares.
-
What Is The Cencora Share Price Today?
Cencora was last trading at $295.76 per share. This represents the most recent stock quote for Cencora. Yesterday, Cencora closed at $291.17 per share.
-
How To Buy Cencora Stock Online?
In order to purchase Cencora stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Where Will KNOT Stock Be In 1 Year?
In the case of KNOT Offshore Partners (KNOP), most headlines…
Why Is Goldman Sachs Stock Up So Much?
Investment banking giant Goldman Sachs (NYSE:GS) has sharply outperformed the…
Stock Ideas
Buy
63
Is NVDA Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 53x
Buy
60
Is MSFT Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 42x
Sell
48
Is AAPL Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 35x
Alerts
Buy
92
BGL alert for Jul 3
Blue Gold [BGL] is down 20.3% over the past day.
Sell
18
CNC alert for Jul 3
Centene [CNC] is down 1.3% over the past day.
Sell
12
MOH alert for Jul 3
Molina Healthcare [MOH] is up 0.3% over the past day.
